PRTC — Puretech Health Balance Sheet
0.000.00%
- £294.85m
- £55.56m
- $4.83m
- 50
- 60
- 39
- 46
Annual balance sheet for Puretech Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 406 | 468 | 352 | 329 | 380 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.94 | 23.2 | 22.4 | 14.1 | 1.52 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 414 | 502 | 386 | 347 | 386 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 42.9 | 43.9 | 37.2 | 19.4 | 15.1 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 990 | 946 | 703 | 694 | 603 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 181 | 226 | 96.9 | 51.4 | 41.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 320 | 352 | 160 | 230 | 188 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 670 | 594 | 542 | 464 | 415 |
| Total Liabilities & Shareholders' Equity | 990 | 946 | 703 | 694 | 603 |
| Total Common Shares Outstanding |